| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shaowei Li, Fumiko Takeuchi, Ji-An Wang, Qingyuan Fan, Toshi Komurasaki, Eric M Billings, Gustavo Pacheco-Rodriguez, Joel Moss, Thomas N Darlin. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 9. 2008-04-18. PMID:18292222. |
patients with tuberous sclerosis complex (tsc) develop hamartomas containing biallelic inactivating mutations in either tsc1 or tsc2, resulting in mammalian target of rapamycin (mtor) activation. |
2008-04-18 |
2023-08-12 |
Not clear |
| Elena A Goncharova, Dmitry A Goncharov, Amelia Chisolm, Matthew S Spaits, Poay N Lim, Gregory Cesarone, Irene Khavin, Omar Tliba, Yassine Amrani, Reynold A Panettieri, Vera P Krymskay. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Molecular pharmacology. vol 73. issue 3. 2008-04-07. PMID:18094073. |
mutational inactivation of tumor suppressor tuberous sclerosis complex 2 (tsc2) in lam constitutively activates the mammalian target of rapamycin (mtor)/p70 s6 kinase 1 (s6k1) signaling pathway and promotes neoplastic growth of lam cells. |
2008-04-07 |
2023-08-12 |
human |
| Franklin C Harwood, Lili Shu, Peter J Houghto. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. The Journal of biological chemistry. vol 283. issue 5. 2008-04-02. PMID:18056704. |
the mtorc1 complex (mammalian target of rapamycin (mtor)-raptor) is modulated by mitogen-activated protein (p44/42 map) kinases (p44/42) through phosphorylation and inactivation of the tuberous sclerosis complex. |
2008-04-02 |
2023-08-12 |
Not clear |
| Lukasz Swiech, Malgorzata Perycz, Anna Malik, Jacek Jaworsk. Role of mTOR in physiology and pathology of the nervous system. Biochimica et biophysica acta. vol 1784. issue 1. 2008-03-27. PMID:17913600. |
recent studies reveal that mtor activity is modified in various pathologic states of the nervous system, including brain tumors, tuberous sclerosis, cortical displasia and neurodegenerative disorders such as alzheimer's, parkinson's and huntington's diseases. |
2008-03-27 |
2023-08-12 |
Not clear |
| Randa M S Amin, Kenzo Hiroshima, Yohei Miyagi, Takeshi Kokubo, Kazuei Hoshi, Takehiko Fujisawa, Yukio Nakatan. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung. Pathology international. vol 58. issue 1. 2008-03-18. PMID:18067639. |
because pathophysiology of several syndromes associated with benign tumors may converge on the tuberous sclerosis complex (tsc), serine/threonine kinase 11 (stk11), and mammalian target of rapamycin (mtor) pathways, the purpose of the present paper was to investigate their roles in the development of sh. |
2008-03-18 |
2023-08-12 |
Not clear |
| Pawel K Wlodarski, Radoslaw Maksym, Monika Oldak, Sergiusz Jozwiak, Andrzej Wojcik, Jaroslaw Jozwia. Tuberin-heterozygous cell line TSC2ang1 as a model for tuberous sclerosis-associated skin lesions. International journal of molecular medicine. vol 21. issue 2. 2008-03-07. PMID:18204792. |
tuberous sclerosis (ts), neurological disorder manifesting with the formation of tumors in numerous organ systems, is a disease associated with the upregulation of mammalian target of rapamycin (mtor) pathway. |
2008-03-07 |
2023-08-12 |
Not clear |
| Z-X Xu, J Liang, V Haridas, A Gaikwad, F P Connolly, G B Mills, J U Gutterma. A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell death and differentiation. vol 14. issue 11. 2008-01-22. PMID:17690712. |
furthermore, avicin d-induced autophagic cell death can be abrogated by knockdown of tuberous sclerosis complex 2 (tsc2), a key mediator linking ampk to mtor inhibition, suggesting that ampk activation is a crucial event targeted by avicin d. these findings indicate the therapeutic potential of avicins by triggering autophagic cell death. |
2008-01-22 |
2023-08-12 |
Not clear |
| Michael J Ravitz, Li Chen, Mary Lynch, Emmett V Schmid. c-myc Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer research. vol 67. issue 23. 2008-01-22. PMID:18056446. |
among mtor signaling components, myc directly affected transcription of tuberous sclerosis 2 (tsc2), as shown by quantitative mrna analysis and by myc binding to its promoter in chromatin immunoprecipitation assays. |
2008-01-22 |
2023-08-12 |
Not clear |
| Quanri Jin, Lei Feng, Carmen Behrens, B Nebiyou Bekele, Ignacio I Wistuba, Waun-Ki Hong, Ho-Young Le. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer research. vol 67. issue 24. 2008-01-15. PMID:18089792. |
deguelin inhibited survivin expression in tuberous sclerosis complex 2 (tsc2) wild-type mouse embryonic fibroblasts (mef) but not in tsc2-knockout mefs in which mammalian target of rapamycin (mtor) is constitutively active. |
2008-01-15 |
2023-08-12 |
mouse |
| John J Bissler, Francis X McCormack, Lisa R Young, Jean M Elwing, Gail Chuck, Jennifer M Leonard, Vincent J Schmithorst, Tal Laor, Alan S Brody, Judy Bean, Shelia Salisbury, David N Fran. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. The New England journal of medicine. vol 358. issue 2. 2008-01-15. PMID:18184959. |
angiomyolipomas in patients with the tuberous sclerosis complex or sporadic lymphangioleiomyomatosis are associated with mutations in tuberous sclerosis genes resulting in constitutive activation of the mammalian target of rapamycin (mtor). |
2008-01-15 |
2023-08-12 |
Not clear |
| Eleonora Aronica, Karin Boer, Marianna Baybis, Jia Yu, Peter Crin. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta neuropathologica. vol 114. issue 3. 2007-12-26. PMID:17483958. |
we hypothesized that mutations in pten (a cause of hmeg associated with proteus syndrome), tsc1 or tsc2 (tuberous sclerosis complex) genes, which are known to modulate beta-catenin and mtor signaling could cause sporadic hmeg. |
2007-12-26 |
2023-08-12 |
Not clear |
| Lisa M Ballou, Elzbieta S Selinger, Jun Yong Choi, Dale G Drueckhammer, Richard Z Li. Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. The Journal of biological chemistry. vol 282. issue 33. 2007-10-19. PMID:17562705. |
signaling through the mammalian target of rapamycin (mtor) is hyperactivated in many human tumors, including hamartomas associated with tuberous sclerosis complex (tsc). |
2007-10-19 |
2023-08-12 |
human |
| Asumthia S Jeyapalan, Renan A Orellana, Agus Suryawan, Pamela M J O'Connor, Hanh V Nguyen, Jeffery Escobar, Jason W Frank, Teresa A Davi. Glucose stimulates protein synthesis in skeletal muscle of neonatal pigs through an AMPK- and mTOR-independent process. American journal of physiology. Endocrinology and metabolism. vol 293. issue 2. 2007-09-24. PMID:17551002. |
the response in muscle was associated with increased phosphorylation of protein kinase b (pkb) and enhanced formation of the active eif4e.eif4g complex but no change in phosphorylation of amp-activated protein kinase (ampk), tuberous sclerosis complex 2 (tsc2), mammalian target of rapamycin (mtor), 4e-binding protein-1 (4e-bp1), ribosomal protein s6 kinase (s6k1), or eukaryotic elongation factor 2 (eef2). |
2007-09-24 |
2023-08-12 |
Not clear |
| Dung-Fang Lee, Hsu-Ping Kuo, Chun-Te Chen, Jung-Mao Hsu, Chao-Kai Chou, Yongkun Wei, Hui-Lung Sun, Long-Yuan Li, Bo Ping, Wei-Chien Huang, Xianghuo He, Jen-Yu Hung, Chien-Chen Lai, Qingqing Ding, Jen-Liang Su, Jer-Yen Yang, Aysegul A Sahin, Gabriel N Hortobagyi, Fuu-Jen Tsai, Chang-Hai Tsai, Mien-Chie Hun. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. vol 130. issue 3. 2007-09-18. PMID:17693255. |
the tuberous sclerosis 1 (tsc1)/tsc2 tumor suppressor complex serves as a repressor of the mtor pathway, and disruption of tsc1/tsc2 complex function may contribute to tumorigenesis. |
2007-09-18 |
2023-08-12 |
human |
| David Neal Fran. mTOR in tuberous sclerosis and other neurological disorders. Epilepsia. vol 48. issue 8. 2007-09-13. PMID:17692052. |
mtor in tuberous sclerosis and other neurological disorders. |
2007-09-13 |
2023-08-12 |
Not clear |
| Li Ma, Julie Teruya-Feldstein, Pauline Bonner, Rosa Bernardi, David Neal Franz, David Witte, Carlos Cordon-Cardo, Pier Paolo Pandolf. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer research. vol 67. issue 15. 2007-09-11. PMID:17671177. |
identification of s664 tsc2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mtor activation in tuberous sclerosis and human cancer. |
2007-09-11 |
2023-08-12 |
human |
| Vera P Krymskay. Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. vol 21. issue 2. 2007-06-12. PMID:17402792. |
however, recent discovery of the tumor suppressor proteins tuberous sclerosis complex 1 (tsc1) and tsc2, also known as hamartin and tuberin, as downstream effectors of pi3k and upstream regulators of the mammalian target of rapamycin (mtor) and s6 kinase 1(s6k1) shed a new light on the pi3k signaling cascade in regulating cell growth and proliferation. |
2007-06-12 |
2023-08-12 |
Not clear |
| Simon J Cook, Simon J Morle. Nutrient-responsive mTOR signalling grows on Sterile ground. The Biochemical journal. vol 403. issue 1. 2007-05-07. PMID:17346240. |
the last few years have seen a remarkable increase in our understanding of the canonical, growth factor-regulated pathway for mtor activation, which is mediated by the class i pi3ks (phosphoinositide 3-kinases), pkb (protein kinase b), tsc1/2 (the tuberous sclerosis complex) and the small gtpase, rheb. |
2007-05-07 |
2023-08-12 |
Not clear |
| Hongbing Zhang, Natalia Bajraszewski, Erxi Wu, Hongwei Wang, Annie P Moseman, Sandra L Dabora, James D Griffin, David J Kwiatkowsk. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. The Journal of clinical investigation. vol 117. issue 3. 2007-05-04. PMID:17290308. |
inactivating mutations of either the tsc1 or the tsc2 tumor-suppressor genes cause tuberous sclerosis complex (tsc), a benign tumor syndrome in which there is both hyperactivation of mtor and inhibition of rtk/pi3k/akt signaling, partially due to reduced pdgfr expression. |
2007-05-04 |
2023-08-12 |
mouse |
| Emilie Vander Haar, Seong-Il Lee, Sricharan Bandhakavi, Timothy J Griffin, Do-Hyung Ki. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nature cell biology. vol 9. issue 3. 2007-04-24. PMID:17277771. |
it was reported that akt activates mtor by phosphorylation and inhibition of tuberous sclerosis complex 2 (tsc2). |
2007-04-24 |
2023-08-12 |
Not clear |